JSPR
Jasper Therapeutics, Inc.NASDAQHealthcare$0.68-0.54%ClosedMarket Cap: $11.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
3.16
P/S
0.00
EV/EBITDA
0.20
DCF Value
$1.44
FCF Yield
-491.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-372.2%
ROA
-211.9%
ROIC
-352.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-15.8M | $-9.1M | $-0.32 | — |
| FY 2025 | $0.00 | NaN% | $-83.9M | $-75.8M | $-3.95 | — |
| Q3 2025 | $0.00 | NaN% | $-19.2M | $-18.7M | $-1.13 | — |
| Q2 2025 | $0.00 | NaN% | $-27.1M | $-26.7M | $-1.74 | — |
| Q1 2025 | $0.00 | NaN% | $-21.8M | $-21.2M | $-1.41 | — |
| Q4 2024 | $0.00 | NaN% | $-25.3M | $-24.3M | $-1.62 | — |
| FY 2024 | $0.00 | NaN% | $-76.2M | $-71.3M | $-4.89 | — |
| Q3 2024 | $0.00 | NaN% | $-19.9M | $-18.6M | $-1.24 | — |
| Q2 2024 | $0.00 | NaN% | $-16.0M | $-14.6M | $-0.97 | — |
| Q1 2024 | $0.00 | -Infinity% | $-15.1M | $-13.7M | $-1.03 | — |
| Q4 2023 | $0.00 | NaN% | $-17.7M | $-16.6M | $-1.50 | — |
| FY 2023 | $0.00 | NaN% | $-68.9M | $-64.5M | $-6.18 | — |